Alteration of the development of mammary hyperplastic alveolar nodules and uterine adenomyosis in SHN mice by different schedules of treatment with CB-154

Mori T, Taketoshi Mori, T Mori, H. Nagasawa, Nagasawa H
Acta endocrinologica · 1984 · vol. 107(2) , pp. 245–249 · doi:10.1530/acta.0.1070245 · PMID:6495991 · W2038603240
Lab / animal OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

CB-154 treatment schedules affected mammary hyperplastic alveolar nodule development differently based on duration and age, while longer treatments beginning early inhibited uterine adenomyosis in mice.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effect of different schedules of bromocriptine-mesilate (CB-154; 0.2 mg/day) treatment on the development of precancerous mammary hyperplastic alveolar nodules (HAN) and uterine adenomyosis was investigated in a virgin SHN strain of mice. CB-154 treatment for 7 weeks beginning at 4 weeks of age enhanced the development of HAN at an advanced age, the shorter period of treatment having no effect. In contrast, spontaneous development of adenomyosis was markedly inhibited in mice treated with CB-154 for more than 4 weeks beginning at 4 weeks of age, but not for less than 3 weeks of the treatment. The inhibitory effect of CB-154 was not counteracted by pituitary grafting. Furthermore, CB-154 treatment between 11 and 18 weeks of age also accelerated HAN formation, but had no effect on the development of adenomyosis. These results indicate that in mice a certain period of CB-154 treatment is necessary to produce changes in the development of HAN and adenomyosis, and that the inhibitory effect of CB-154 on the development of adenomyosis is age-dependent. The different response between mammary gland cells and uterine cells to CB-154 exposure is discussed with special reference to cell proliferation.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Breast Breast Neoplasms Bromocriptine Endometriosis Precancerous Conditions Uterine Neoplasms Uterus Age Factors Age Factors Animals Animals Breast Breast Breast Breast Neoplasms Breast Neoplasms Bromocriptine Bromocriptine Dose-Response Relationship, Drug Dose-Response Relationship, Drug

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (9)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:58:15.129929+00:00
License: CC0 · commercial use OK